within Pharmacolibrary.Drugs.ATC.V;

model V03AE05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,
    adminCount     = 1,
    Vd             = 0,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Sucroferric oxyhydroxide is a non-calcium, iron-based phosphate binder used to control serum phosphorus levels in adult patients with chronic kidney disease (CKD) on dialysis. It is administered orally and works by binding dietary phosphate in the gastrointestinal tract, thereby reducing absorption and serum phosphate concentration. Sucroferric oxyhydroxide is approved for use in many countries including the US and EU.</p><h4>Pharmacokinetics</h4><p>No pharmacokinetic absorption of sucroferric oxyhydroxide as an intact compound has been observed; it acts locally in the gastrointestinal tract in adult CKD patients on dialysis. Minimal iron absorption reported, none quantifiable as a central PK model.</p><h4>References</h4><ol><li><p>Greig, SL, &amp; Plosker, GL (2015). Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis. <i>Drugs</i> 75(5) 533–542. DOI:<a href=&quot;https://doi.org/10.1007/s40265-015-0366-1&quot;>10.1007/s40265-015-0366-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25761962/&quot;>https://pubmed.ncbi.nlm.nih.gov/25761962</a></p></li><li><p>Floege, J, et al., &amp; Sprague, SM (2020). Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammation. <i>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</i> 35(6) 946–954. DOI:<a href=&quot;https://doi.org/10.1093/ndt/gfaa030&quot;>10.1093/ndt/gfaa030</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32259248/&quot;>https://pubmed.ncbi.nlm.nih.gov/32259248</a></p></li><li><p>Yaguchi, A, et al., &amp; Takeda, H (2019). A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study. <i>BMC nephrology</i> 20(1) 465–None. DOI:<a href=&quot;https://doi.org/10.1186/s12882-019-1655-9&quot;>10.1186/s12882-019-1655-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31830936/&quot;>https://pubmed.ncbi.nlm.nih.gov/31830936</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V03AE05;
